To evaluate the clinical effects of Bushen Yizhi Formula on Alzheimer's disease.Methods:CNKI，PubMed，CSPD，CCD，CBM，EMbase，Medline and the Cochrane library were searched by computer from the establishment of the database to January 2020.Relevant studies were included，and Revman 5.3 software was used for data analysis and evaluation.Results:A total of 31 papers were included，involving 2 730 patients.1)Among them，the experimental group was a prescription for Bushen Yizhi Formula and the control group is donepezil hydrochloride tablets.The total effective rate was RR=1.21[1.13，1.29]，P<0.01; MMSE score：MD=1.91[-0.17，3.99]，P=0.07; ADL score：MD=-3.35[-5.70,-1.00]，P<0.01; ADAS cog score：MD=-5.51[-7.68,-3.35]，P<0.01).Compared with the control group，the experimental group had a higher total effective rate.ADL score and ADAS-cog score were lower，and MMSE score had no significant change.2)The experimental group was Bushen Yizhi Formula，while the control group was zolpidem tablets.The total effective rate：RR=1.24[1.17，1.31]，P<0.01; MMSE score：MD=4.82[2.52，7.11]，P<0.01.The total effective rate of the experimental group was higher than that of the control group，and MMSE score was higher.Due to the limitation of the safety evaluation of the included researches and reports，its safety still needs to be further verified by clinical trials.Conclusion:Bushen Yizhi Formula can improve the total effective rate，MMSE score，ADL score and ADAS-cog score of Alzheimer's disease patients to a certain extent，improve the cognitive function and living ability of patients，and provide some basis for clinical practice.